fda glp 1 green list introduces "Green List" for GLP-1 drug ingredients Food and Drug Administration Launches

Diabetes 64 , 16881697 (2015)

Underlying cardiovascular disease: Many patients prescribed GLP-1 medications have cardiovascular risk factors or established heart disease

At the 23andMe Research Institute, we are proud to have built a model we call the "research flywheel." The flywheel is a cycle of research engagement and creation of novel genetic reports

that bone loss was most pronounced in weight-bearing skeletal sites, with no significant changes in non-weight-bearing areas such as the radius, suggests that mechanical unloading may be a key driver of bone resorption rather than a direct pharmacologic effect of GLP-1 receptor activation

Participant characteristics were described using mean (standard deviation) and frequencies, and compared between groups using a t-test and Chi-square test where appropriate